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ABO incompatibility (ABO-I) is known to produce hemo-
lytic complications including acute hemolysis, passenger
lymphocyte syndrome, delayed transfusion dependence, and
pure red cell aplasia [1]. However, ABO-I has not been known
to exert an impact on survival or nonrelapse mortality (NRM)
in early transplantation literature [2,3]. Resnick et al. have
shown in a contrary report that ABO-I increased NRM in the
reduced-intensity transplantation setting [4]. ABO antigens
are expressed on a wide range of human tissues, apart from
RBCs, including epithelial and endothelial cells [5,6]. Anti-
bodies against ABO expressed on the endothelial surfaces of
vessels in solid organ transplantations are responsible for
mediating acute rejection [7]. Given the expression of ABO
on the endothelium, it appears plausible that minor ABO-I
might affect NRM, especially in settings where graft-
versus-host disease is not the most important contributor
to NRM. We conducted a large retrospective study to eval-
uate the hypothesis that minor ABO-I impacts overall sur-
vival (OS) and NRM in T celledepleted allogeneic stem cell
transplantation.
We analyzed 374 patients who had undergone allogeneic
transplantations for hematologic malignancies from HLA-
matched sibling donors between the years 1993 and 2014.
Fifty-ﬁve patients had major, 71 patients had either minor or
bidirectional (minor/bi), and 248 patients had no ABO-I. TheFinancial disclosure: See Acknowledgments on page 954.
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sixty-two (43%) had acute myeloid leukemia/myelodys-
plastic syndrome, 120 (32%) had chronic myeloid leukemia/
chronic myelomonocytic leukemia, 63 (17%) had acute
lymphoblastic leukemia, 18 (5%) had non-Hodgkin leukemia/
chronic lymphoblastic leukemia, and 14 (4%) had other
diagnoses. Three hundred forty-four (92%) received a cyclo-
phosphamide/total body irradiationebased myeloablative
conditioning, and 30 (8%) received reduced-intensity condi-
tioning. The graft source was peripheral blood stem cells in
336 (90%) and bone marrow in 38 (10%), and it was ex vivo T
cell depleted in 99%. There were no signiﬁcant differences
between minor ABO-I and other groups with respect
to baseline variables. Kaplan-Meier estimates were used to
determine OS, NRM, and the cumulative incidence of relapse,
with differences between groups determined by the log-rank
test.
At a median follow-up of 11 years, the OS for minor/bi
ABO-I was 43% versus 40% for others (P ¼ .80). NRM was 38%
for minor/bi ABO-I versus 42% for others (P ¼ .60). The cu-
mulative incidence of relapse was 58% for minor/bi ABO-I
versus 50% for others (P ¼ .10). Findings were similar when
ABO-I status was categorized into 3 groups (major, minor/bi,
no ABO-I). We concluded from this large study of mostly
myeloablative, T celledepleted allogeneic transplantation
patients that the presence of ABO-I did not signiﬁcantly
affect long-term OS and NRM.
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